AQST
Aquestive Therapeutics Inc (AQST)
Healthcare • NASDAQ • $4.32+2.13%
- Symbol
- AQST
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $4.32
- Daily Change
- +2.13%
- Market Cap
- $536.91M
- Trailing P/E
- N/A
- Forward P/E
- -7.45
- 52W High
- $7.55
- 52W Low
- $2.12
- Analyst Target
- $8.89
- Dividend Yield
- N/A
- Beta
- 1.50
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epineph…
Company websiteResearch AQST on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.